Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 193Lung Neoplasms 80Pancreatic Neoplasms 47Neoplasms 31Non-Squamous Non-Small Cell Lung Cancer 19Head and Neck Neoplasms 19Glioblastoma 19Adenocarcinoma of Lung 19Squamous Cell Carcinoma of Head and Neck 18Neoplasm Metastasis 17Gliosarcoma 17Brain Neoplasms 17Breast Neoplasms 16Rectal Neoplasms 13Colorectal Neoplasms 13Colonic Neoplasms 13Adenocarcinoma, Bronchiolo-Alveolar 13Carcinoma, Hepatocellular 11Carcinoma, Renal Cell 10Glioma 8Astrocytoma 8Salivary Gland Neoplasms 7Gallbladder Neoplasms 7Esophageal Neoplasms 7Carcinoma, Ovarian Epithelial 7Prostatic Neoplasms 6Ovarian Neoplasms 6Oligodendroglioma 6Fallopian Tube Neoplasms 6Carcinoma, Squamous Cell 6

Interventions

seribantumab 2zenocutuzumab 1patritumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1In Situ Hybridization, Fluorescence 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lethal Congenital Contracture Syndrome 2 × Erlotinib Hydrochloride × Clear all
NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Merrimack Pharmaceuticals

Phase 1/2 Completed
162 enrolled 11 charts
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡